SCHEDULE: Northstrive Fund II LP, Lichti Disclose 5.01% Stake in Enveric

Sentiment:

Beneficial Ownership Disclosure 5 December 2025 5:40 PM

📋All filings for Enveric Biosciences, INC

Northstrive Fund II LP and Braeden Lichti have disclosed a combined beneficial ownership of 5.01% of Enveric Biosciences, Inc.'s common stock.

Summary

Northstrive Fund II LP and Braeden Lichti (collectively, "Reporting Persons") have filed a Schedule 13G, indicating beneficial ownership in Enveric Biosciences, Inc.
The Reporting Persons collectively beneficially own 29,920 shares of Enveric Biosciences, Inc. common stock.
This ownership represents 5.01% of the company's outstanding common stock.
The percentage is calculated based on 596,978 shares of common stock outstanding as of November 12, 2025, as reported in the Issuer's Form 10-Q.
The event requiring this filing, which is the acquisition of beneficial ownership exceeding 5%, occurred on December 3, 2025.
Braeden Lichti, as the Manager of Northstrive Fund II LP, is deemed to beneficially own the securities held by the fund, in addition to his individually held shares.

Sentiment

Score: 6

Explanation: The disclosure of a new significant shareholder (5.01%) is generally viewed as a neutral to slightly positive event, indicating investor interest, but without further context on the investor's intentions, it's not strongly positive or negative.

Positives

A new significant shareholder, Braeden Lichti, has acquired a 5.01% stake, potentially signaling confidence in Enveric Biosciences.

Future Outlook

Industry Context

Stakeholder Impact

Shareholders: The entry of a new significant shareholder could be seen as a vote of confidence, potentially influencing market perception and liquidity.

Key Dates

Date	Description
2025-11-12	Date as of which 596,978 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q.
2025-11-14	Date Issuer's Form 10-Q was filed with the SEC.
2025-12-03	Date of event which required the filing of this statement (crossing the 5% beneficial ownership threshold).
2025-12-05	Date the Schedule 13G was signed and filed.

Recommendation

hold

The filing indicates a new significant shareholder has acquired a 5.01% stake in Enveric Biosciences. While this signals investor interest, a Schedule 13G is a passive filing, meaning the investor does not currently intend to influence control. Without further information on the investor's long-term intentions or any new fundamental company data, the filing alone does not warrant a change from a 'hold' position. It's a disclosure of ownership, not a performance update.

Keywords

Enveric Biosciences, EVBC, Schedule 13G, Beneficial Ownership, Northstrive Fund II LP, Braeden Lichti, Common Stock, SEC Filing, Shareholder Stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.